FDA Clearance Tracker · P250033-S004
NEXUS Aortic Arch Stent Graft System
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 21, 2026
Approved
Time to decision
90 days
Received Jun 23, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P250033-S004
- Device name
- NEXUS Aortic Arch Stent Graft System
- Applicant
- Endospan , Ltd.
- Applicant location
- Alta, WY
- Received
- Jun 23, 2026
- Decided
- Sep 21, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P250033
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
approval for a 3 year shelf-life for the NEXUS Aortic Arch Stent Graft System
Source documents
Other decisions for Endospan , Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- NEXUS Aortic Arch Stent Graft SystemBreakthroughPMA
P250033 · Decided Apr 2, 2026 · 223 days after receipt
Device type: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions (SDZ) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.